8-K: Ovid Therapeutics Provides Business Update and Third Quarter 2024 Financial Results

Ovid Therapeutics reported its third quarter 2024 financial results, provided a business update, and announced a strategic pause in a Phase 2 study.

Summary

• Ovid Therapeutics announced its third quarter 2024 financial results, reporting a net loss of $14.0 million, or $0.20 per share, compared to a net loss of $11.3 million, or $0.16 per share, for the same period in 2023.
• The company's cash and marketable securities totaled $62.7 million as of September 30, 2024, which is expected to fund operations into the second half of 2026.
• Ovid is progressing its pipeline, including OV329, a next-generation GABA-AT inhibitor, and OV350, the first candidate from its KCC2 direct activator library.
• A Phase 1 study of OV329 is progressing as planned, with potential for additional cohorts to increase dosing opportunities for Phase 2 programs.
• The company expects to file a regulatory application for a Phase 1 trial of OV350 in Q4 2024 and initiate the trial in Q1 2025.
• Ovid and Graviton are pausing the initiation of a Phase 2 study of OV888/GV101 to evaluate emerging insights from competitor trials in cerebral cavernous malformations (CCM).
• Revenues from royalty agreements were $173,000 for the third quarter of 2024, compared to $109,000 in the same period in 2023.
• Research and development expenses increased to $7.9 million in Q3 2024 from $5.3 million in Q3 2023, due to the advancement of pipeline programs.
• General and administrative expenses decreased to $5.5 million in Q3 2024 from $6.8 million in Q3 2023, due to cost-reduction efforts.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive progress in some areas (pipeline advancement, safety data) but also negative aspects (increased net loss, study pause). The strategic pause in the Phase 2 study is a concern, but the company's focus on data-driven decisions is a positive sign. The sentiment is cautiously optimistic.

Positives

• The company's cash runway is expected to extend into the second half of 2026.
• OV329 is showing promising safety data in its Phase 1 study, with potential for increased dosing opportunities.
• OV350 is progressing towards a Phase 1 trial, with a regulatory application expected by the end of 2024.
• Ovid's KCC2 direct activator library is progressing, with multiple compounds showing potential for various neurological conditions.
• Ovid has demonstrated that OV329 does not accumulate in the eye, unlike vigabatrin, which is a positive safety signal.
• The company has strengthened its leadership team with key appointments.
• Revenues from royalty agreements increased compared to the same period last year.
• General and administrative expenses decreased due to cost-reduction efforts.

Negatives

• Ovid reported a net loss of $14.0 million for the third quarter of 2024, which is an increase from the $11.3 million loss in the same period of 2023.
• The company is pausing the initiation of a Phase 2 study of OV888/GV101, which may delay the development of this program.
• Research and development expenses increased compared to the same period last year.

Risks

• The company faces risks inherent in the preclinical and clinical development and regulatory approval processes.
• There are risks related to the company's ability to achieve its financial objectives.
• Ovid may not be able to realize the intended benefits of its technology or business strategy.
• The company may face challenges in identifying business development targets or strategic partners.
• There is a risk that Ovid may not be able to enter into strategic transactions on favorable terms or consummate and realize the benefits of any business development transactions.
• The pause in the OV888/GV101 Phase 2 study could lead to delays and increased costs.

Future Outlook

Ovid expects its cash runway to support operations and clinical development into H2 2026, during which time they plan to achieve multiple clinical and regulatory milestones associated with its OV329 and OV350 programs, and to advance undisclosed ROCK2 inhibition programs. The company will also explore partnerships and co-development opportunities for select programs.

Management Comments

• Dr. Jeremy Levin, Chair and CEO, stated that the company is poised to address significant unmet needs in diseases of the central nervous system.
• Dr. Levin also mentioned that the company is channeling resources toward programs with the greatest potential to deliver meaningful clinical outcomes and pivotal milestones within their financial runway.
• The company made a proactive decision to pause the initiation of the Phase 2 program in CCM to incorporate fresh insights from recent competitor trials.

Industry Context

The biopharmaceutical industry is entering an exciting new era of neurotherapeutics, and Ovid is positioning itself to address unmet needs in central nervous system disorders. The company's focus on differentiated mechanisms of action, such as GABA-aminotransferase inhibition, KCC2 direct activation, and ROCK2 inhibition, aligns with the industry's trend towards targeted therapies.

Comparison to Industry Standards

• Ovid's approach to GABA-AT inhibition with OV329 is differentiated from older drugs like vigabatrin, aiming for less sedation and no ocular changes, which is a key concern in the field.
• The development of KCC2 direct activators like OV350 is a novel approach in the CNS space, targeting a fundamental mechanism of neuronal homeostasis, which is not widely pursued by other companies.
• The strategic pause in the OV888/GV101 Phase 2 study to incorporate learnings from competitor trials demonstrates a responsible approach to clinical development, which is common in the industry to optimize trial design and outcomes.
• Ovid's cash runway extending into H2 2026 is a positive sign, indicating financial stability compared to other biotech companies that may face funding challenges.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the pause in the OV888/GV101 Phase 2 study.
• Employees may be impacted by the company's cost-reduction efforts and the strategic shift in pipeline priorities.
• Patients with brain conditions may benefit from the development of new therapies such as OV329 and OV350.
• Partners and collaborators may be affected by the company's strategic decisions and pipeline prioritization.

Next Steps

• Ovid will engage regulators about adding cohorts to the Phase 1 SAD/MAD study of OV329.
• The company expects to submit a regulatory application for a Phase 1 trial of OV350 in Q4 2024.
• Ovid will initiate first-in-human studies for OV350 in Q1 2025.
• Ovid and Graviton will evaluate clinical design learnings from competitor trials to optimize future development approaches for OV888/GV101.
• Ovid will present full results from a head-to-head study of OV329 and vigabatrin at the 2024 American Epilepsy Society conference in December.
• Ovid will host a KCC2 Download Day on November 13 to provide updates on its KCC2 direct activator platform.

Key Dates

Keywords

Ovid Therapeutics, OV329, OV350, KCC2, GABA-AT inhibitor, Neurotherapeutics, Clinical Trials, Phase 1, Phase 2, Financial Results, Cerebral Cavernous Malformations, ROCK2 inhibitor